A Phase 2 Study of Erdafitinib for Progressive Brain Cancers With a Gene Fusion


Full Title

A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion (NCI 10559) (CIRB)


Researchers are assessing how well erdafitinib works to treat gliomas that keep growing after treatment. The people in this study have glioma with a normal IDH gene and a fusion of two other genes (FGFR-TACC).

Erdafitinib blocks the action of the abnormal FGFR protein, which tells tumor cells to multiply. Giving erdafitinib may help to slow or shrink glioma growth in people with the FGFR-TACC gene fusion. Erdafitinib is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a glioma that keeps growing after treatment and has normal IDH and an FGFR-TACC gene fusion.
  • Have recovered from the serious side effects of prior therapies before taking erdafitinib.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call 212-610-0261. You may also call Dr. Thomas Kaley’s office at 212-639-5122.




Phase II (phase 2)



ClinicalTrials.gov ID